Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 55, Issue 7, 2016, Pages 1210-1216

  Van Breukelen van der Stoep, Deborah F ^a   Van Zeben, Derkjen ^a   Klop, Boudewijn ^a   Van de Geijn, Gert Jan M ^a   Janssen, Hans J W ^a   Meulen, Noelle van der ^a   De Vries, Marijke A ^a   Hazes, Mieke ^b   Birnie, Erwin ^c,d   Cabezas, Manuel Castro ^a  

^a Department of Rheumatology ^*  (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d Sint Franciscus Gasthuis Rotterdam   (Netherlands)

Author keywords

Cardiovascular risk; Rheumatoid arthritis; Risk assessment

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; C REACTIVE PROTEIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAS28; DIAGNOSIS; DISEASE DURATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; THERAPY; UNDERDIAGNOSIS; UNDERTREATMENT; BLOOD; BLOOD PRESSURE; COMPLICATION; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; PROCEDURES; RISK FACTOR;

ADULT; ANTIHYPERTENSIVE AGENTS; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 84977098188     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew039     Document Type: Article

References (29)

1. van Halm VP, Peters MJ, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009;68:1395-400.
2. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
3. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
4. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
5. del Rincón I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52:3413-23.
6. van Breukelen-van der Stoep DF, Klop B, van Zeben D, Hazes JM, Cabezas MC. Cardiovascular risk in rheumatoid arthritis: how to lower the risk? Atherosclerosis 2013;231:163-72.
7. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30.
8. Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 2009;4:e6242.
9. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence- based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
10. Wiersma T, Smulders YM, Stehouwer CD, Konings KT, Lanphen J. [Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)]. Ned Tijdschr Geneeskd 2012;156:A5104.
11. Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology 2008;47:1286-98.
12. Chung CP, Giles JT, Petri M, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 2012;41:535-44.
13. Hermans MP, Castro Cabezas M, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010;26:445-54.
14. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40.
15. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37.
16. Manavathongchai S, Bian A, Rho YH, et al. Inflammation and hypertension in rheumatoid arthritis. J Rheumatol 2013;40:1806-11.
17. Stamatelopoulos KS, Kitas GD, Papamichael CM, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009;29:1702-8.
18. Holmqvist ME, Wedrén S, Jacobsson LT, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010;268:578-85.
19. Södergren A, Karp K, Boman K, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010;12:R158.
20. Gómez-Vaquero C, Robustillo M, Narváez J, et al. Assessment of cardiovascular risk in rheumatoid arthritis: impact of the new EULAR recommendations on the score cardiovascular risk index. Clin Rheumatol 2012;31:35-9.
21. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population- based retrospective cohort study. Lancet 2006;368:29-36.
22. Conroy RM, PyöräläK, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
23. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.
24. Semb AG, Rollefstad S, van Riel P, et al. Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice. Ann Rheum Dis 2014;73:1284-8.
25. Arts EE, Popa CD, Den Broeder AA, et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis 2015;
26. Sheng X, Murphy MJ, Macdonald TM, Wei L. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol 2012;39:32-40.
27. Flammer AJ, Sudano I, Hermann F, et al. Angiotensinconverting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008;117:2262-9.
28. Rollefstad S, Kvien TK, Holme I, et al. Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. Ann Rheum Dis 2013;72:1968-74.
29. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.